FDA CMC interactions: timing questions, data packages, and common gaps before PDUFA

The months before a PDUFA goal date are rarely quiet. Clinical and safety topics often dominate executive attention, yet Chemistry, Manufacturing, and Controls questions can determine whether a review stays on track. Understanding how and when CMC issues surface — and what a complete response looks like — helps teams avoid scrambling for data they could have staged earlier.

Why CMC questions spike late

Review teams work in parallel, but CMC assessment often depends on cross-functional dependencies: stability updates, comparability after process changes, facility information, and control strategy alignment across modules. When those threads do not meet the reviewer’s mental model of risk, questions follow. The timing can feel abrupt to sponsors who believed the manufacturing story was settled at filing.

Patterns we help clients prepare for

1. Completeness: Missing or hard-to-navigate linkage between process description, specifications, and batch data for pivotal lots.
2. Change control: Late changes to sites, equipment, or suppliers that require clearer impact assessment and updated validation evidence.
3. Analytical strategy: Methods and acceptance criteria that evolved during development without a concise summary of the final approach.

The goal is not to predict every question. It is to build a response system: owners, data sources, and timelines that can withstand scrutiny without draining the team before approval.

Information requests and your narrative

Formal information requests are only one channel. Informal clarification and mid-cycle communication can surface CMC topics as well. Strong programs maintain a living “CMC story” document: what changed since the last filing, why it is acceptable, and where evidence lives in the eCTD. That document is not submitted as-is — it is a rehearsal aid so regulatory and technical leads speak with one voice when time is short.

Meetings with the agency — for example, Type C discussions on manufacturing or control topics when appropriate — can reduce ambiguity earlier, but they require disciplined preparation and clear objectives. Used well, they narrow the hypothesis space; used poorly, they burn credibility.

Verta’s regulatory and CMC consultants work with sponsors on briefing packages, response strategy, and CDMO coordination through late-stage review. To discuss your program, reach out to our team or read more about regulatory affairs support.